For Pancretic Cancer Awareness month, CancerNetwork® spoke with Manuel Hidalgo Medina, MD, PhD, about the importance of the phase 2 COMBAT/KEYNOTE-202 trial examining motixafortide and pembrolizumab plus nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic ductal adenocarcinoma.

Patients with advanced renal cell carcinoma who received first-line nivolumab and ipilimumab experienced an improved treatment-free survival vs sunitinib.

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Zofia Piotrowska, MD, discusses the role of amivantamab in the treatment of patients with NSCLC and EGFR exon 20 insertions.

A exposure-response analysis indicated that a 3.2mg/m2 dose of lurbinectedin every 3 weeks achieved a favorable risk/benefit profile in patients with small cell lung cancer.

Zofia Piotrowska, MD, reviews historical treatment approaches for patients with NSCLC and EGFR exon 20 insertions.

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Considerations regarding treatment selection for patients with steroid-refractory chronic graft-vs-host disease based on current unmet needs and newer therapies in the pipeline.

Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.

Reactions to a case of chronic graft-vs-host disease and thoughts on sequencing therapy.